Page 1 Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818 30 September 2026 Sydney, Australia Nyrada US Patent for Xolatryp® Granted Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor...
Nyrada US Patent for Xolatryp Granted
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Nyrada
- Cleansing Statement
- Application for quotation of securities - NYR
- Proposed issue of securities - NYR
- Cap Raise Deck-Building the Future of TRPC-based Therapies
- Nyrada Successfully Raises AU$12.0 Million Via Placement
Later from Nyrada
- 2026 AGM Letter to Shareholders, Notice of Meeting & Proxy
- Securities Purchase Plan Offer Booklet
- Attaching Options Prospectus
- Nyrada Receives Positive FDA Feedback
- PROTECT-MI Phase IIa Clinical Trial Update No 3
Follow Nyrada into a list and get an email when it puts out news.
Follow Nyrada